IL311801A - Dosage regimen of factor XI/XIA antibodies - Google Patents

Dosage regimen of factor XI/XIA antibodies

Info

Publication number
IL311801A
IL311801A IL311801A IL31180124A IL311801A IL 311801 A IL311801 A IL 311801A IL 311801 A IL311801 A IL 311801A IL 31180124 A IL31180124 A IL 31180124A IL 311801 A IL311801 A IL 311801A
Authority
IL
Israel
Prior art keywords
factor
dosing regimens
xia antibodies
xia
antibodies
Prior art date
Application number
IL311801A
Other languages
English (en)
Hebrew (he)
Inventor
Daniel M Bloomfield
Debra A Freedholm
Jonathan E Freeman
Royston J Glasspool
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Daniel M Bloomfield
Debra A Freedholm
Jonathan E Freeman
Royston J Glasspool
Yasser Khder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc, Daniel M Bloomfield, Debra A Freedholm, Jonathan E Freeman, Royston J Glasspool, Yasser Khder filed Critical Anthos Therapeutics Inc
Publication of IL311801A publication Critical patent/IL311801A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL311801A 2021-11-18 2022-11-18 Dosage regimen of factor XI/XIA antibodies IL311801A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163281024P 2021-11-18 2021-11-18
US202163287633P 2021-12-09 2021-12-09
US202263355314P 2022-06-24 2022-06-24
PCT/US2022/080131 WO2023092062A1 (en) 2021-11-18 2022-11-18 Dosing regimens of factor xi/xia antibodies

Publications (1)

Publication Number Publication Date
IL311801A true IL311801A (en) 2024-05-01

Family

ID=86397863

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311801A IL311801A (en) 2021-11-18 2022-11-18 Dosage regimen of factor XI/XIA antibodies

Country Status (8)

Country Link
US (1) US20240294669A1 (enExample)
EP (1) EP4433088A4 (enExample)
JP (1) JP2024540435A (enExample)
KR (1) KR20240109269A (enExample)
CA (1) CA3234626A1 (enExample)
IL (1) IL311801A (enExample)
TW (1) TW202334239A (enExample)
WO (1) WO2023092062A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
JP2023507795A (ja) * 2019-12-20 2023-02-27 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
US20250388679A1 (en) * 2024-06-20 2025-12-25 argenx BV Subcutaneous fcrn antagonist formulations and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015176012A1 (en) * 2014-05-15 2015-11-19 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
JOP20160131B1 (ar) * 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP2023507795A (ja) * 2019-12-20 2023-02-27 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Also Published As

Publication number Publication date
JP2024540435A (ja) 2024-10-31
EP4433088A4 (en) 2026-01-14
TW202334239A (zh) 2023-09-01
WO2023092062A1 (en) 2023-05-25
KR20240109269A (ko) 2024-07-10
US20240294669A1 (en) 2024-09-05
CA3234626A1 (en) 2023-05-25
EP4433088A1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
IL276872A (en) Dosage for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
IL311039A (en) Anti-cd3 antibodies
DK3389699T3 (da) Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf
SI4076385T1 (sl) Formulacije protiteles anti-pd1
DK3286223T5 (da) Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf
ZA201907065B (en) Monoclonal antibody to pd-l1
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
EP3705134A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
SG11201911598WA (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
IL276623A (en) Dosing regimens of B7-H4 antibody
IL273419A (en) Dosage regimens of siphonimod
EA201791049A1 (ru) Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
HUE069403T2 (hu) Anti-PD-1 antitestek
PL3894457T3 (pl) Powłoki proszkowe do epoksydowo-aminowych prętów zbrojeniowych łączonych metodą stapiania
PT4340842T (pt) Sotorasib para utilização no tratamento de cancro
ZA202102874B (en) Monoclonal antibody that specifically binds to cd20
IL276636A (en) Specific expression in the tumor environment of chimeric antigen receptors
EP4433088A4 (en) ANTI-FACTOR XI/XIA ANTIBODY DOSAGES
IL309664A (en) Administration of anti-HPA-1A antibodies
ZA202002044B (en) Monoclonal antibody to il-5rα
IL266769A (en) Monoclonal antibodies specific for fgfr1 and their preparation
IL273382A (en) Dosage regimens of siphonimod
EP3955925A4 (en) HUMANIZED ANTI-PD-L1 ANTIBODIES
GB202107303D0 (en) Cover structure of sealed can
IL311022A (en) Peptide-targeted chimeric antigen receptors for cancer self-peptides